Technology ID
TAB-3426

P2Y14 Receptor Antagonists Containing A Biaryl Core

E-Numbers
E-028-2018-0
E-028-2018-1
Lead Inventor
Jacobson, Kenneth (NIDDK)
Co-Inventors
Yu, Jinha (NIDDK)
Ciancetta, Antonella (NIDDK)
Wen, Zhiwei (NIDDK)
Jung, Young-Hwan (NIDDK)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Pulmonology
Immunology
Endocrinology
Development Stages
Pre-Clinical (in vitro)
Research Products
Research Equipment
Lead IC
NIDDK
ICs
NIDDK
The technology discloses composition of compounds that fully antagonize the human P2Y14 receptor, with moderate affinity with insignificant antagonism of other P2Y receptors. Therefore, they are highly selective P2Y14 receptor antagonists. Even though there is no P2Y14 receptor modulators in clinical use currently, selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, cystic fibrosis, inflammation and possibly diabetes and neurodegeneration.
Commercial Applications
  • Development of P2Y14 receptor antagonist for treatment of disorders, such as:
  • Inflammation
  • diabetes
  • cystic fibrosis
  • asthma
  • neurodegeneration
  • metabolic syndromer

    • Request More Info

    Licensing Contact:
    Tong, Betty
    tongb@niddk.nih.gov

    Patents

    • US
      Provisional (PRV) 62/628,699
      Filed on 2018-02-09
    • Patent Cooperation Treaty
      Patent Cooperation Treaty Combined (PCT COMB) PCT/US19/17422
      Filed on 2019-02-11
    • US Patent 11,584,736
      Filed on 2020-08-04

    Publications

    • Yu J, et al, Structure-guided modification of heterocyclic antagonists of the P2Y14 receptor. J. Med. Chem., 2018, 61: 4860-4882, (doi: 10.1021/acs.jmedchem.8b00168 )
    • Jung, Y.H., et al, Exploration of alternative scaffolds for P2Y14 receptor antagonists containing a biaryl core. J. Med. Chem., 2020, 63:9563–9589 (doi: 10.1021/acs.jmedchem.0c00745)

    Collaborations

    • Collaboration

    Collaboration Description

    • The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize P2Y14 Receptor Antagonists Containing A Biaryl Core. For collaboration opportunities, please contact Kenneth A. Jacobson, Ph.D. at ,a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov
    Date Published